Quell Therapeutics Makes Significant Progress in Cell Therapy Initiatives
Quell Therapeutics has recently announced a remarkable milestone in their CAR-Treg cell therapy program targeting inflammatory bowel disease (IBD). In a significant development, AstraZeneca has decided to license their first candidate from this innovative research program, emphasizing the growing collaboration between these two companies.
AstraZeneca and Quell Collaborate for Advancement
This achievement signals AstraZeneca's commitment to advancing the new therapy, as it fulfills the second significant research milestone in the ongoing partnership with Quell Therapeutics. In connection with this milestone, Quell has been granted a $10 million payment from AstraZeneca, further cementing their collaborative efforts.
Commitment to Research and Development
Quell Therapeutics will take on the crucial role of managing chemistry, manufacturing, and controls (CMC) to support the clinical trial application (CTA) and investigational new drug (IND) enabling studies. They will also ensure the production of clinical-grade materials necessary for the upcoming first-in-human trial.
The Impact of This Collaboration
Iain McGill, the CEO of Quell Therapeutics, expressed enthusiasm about the fruitful partnership with AstraZeneca. He remarked on how achieving this milestone represents not just progress in IBD but also reflects their innovative approach in treating other complex immune-mediated diseases. McGill highlighted the advances being made in their proprietary clinical program aimed at helping liver transplant patients through the QEL-001 candidate.
Future Prospects in Medicine
Attilio Bondanza, VP of Immunology Cell Therapy at AstraZeneca, shared insights about the increasing burden of inflammatory bowel disease. He underlined the necessity for new and innovative treatments to tackle the underlying causes of these conditions, expecting Quell’s therapies to offer a transformative solution for patients in need.
About the Strategic Agreement
This promising collaboration between Quell and AstraZeneca began with an exclusive option and license agreement in 2023, aimed at developing groundbreaking therapies for two challenging autoimmune diseases: Type 1 Diabetes (T1D) and IBD. The partnership utilizes Quell's cutting-edge Treg cell engineering technologies, including advancements in their Foxp3 Phenotype Lock.
Quell Therapeutics: A Leader in Immune System Therapy
Quell has positioned itself as a frontrunner in engineered T-regulatory (Treg) cell therapies that tackle serious immune-related medical conditions. Utilizing its unique technology and integrated manufacturing capabilities, the company aims to create a robust pipeline of Treg therapies characterized by enhanced persistence and stability.
Lead Candidate and Clinical Trials
The development of QEL-001, their lead candidate, is currently in the LIBERATE Phase 1/2 clinical trial. This trial seeks to evaluate its efficacy in inducing operational tolerance in liver transplant patients, representing a potential landmark in reducing reliance on chronic immunosuppressive drugs. Alongside their endeavors in IBD, Quell is also advancing its programs in Type 1 Diabetes, showcasing a broad commitment to innovation in the biotech field.
Frequently Asked Questions
What recent milestone did Quell Therapeutics achieve?
Quell Therapeutics achieved a significant milestone by having AstraZeneca license their first CAR-Treg cell therapy candidate for inflammatory bowel disease.
How much funding did Quell receive from AstraZeneca?
Quell received a payment of $10 million from AstraZeneca in connection with the milestone achievement.
What role is Quell playing in the clinical trial process?
Quell will manage chemistry, manufacturing, and controls while supporting the necessary studies for the first human trial.
What is Quell's lead candidate focused on?
Quell's lead candidate, QEL-001, is designed to enhance immune tolerance in liver transplant patients.
When are the results from the LIBERATE trial expected to be shared?
Quell anticipates sharing the first efficacy data from the LIBERATE trial later this year.
